NCT07318727 Comparative Study on the Effect of Diet Interventions on Weight Loss in Overweight Endometrial Cancer Patients Undergoing Fertility-sparing Treatment
| NCT ID | NCT07318727 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking University People's Hospital |
| Condition | Endometrium Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 81 participants |
| Start Date | 2025-01-10 |
| Primary Completion | 2026-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 81 participants in total. It began in 2025-01-10 with a primary completion date of 2026-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In this study, overweight and obese patients with endometrial cancer treated with fertility- sparing therapy were randomly divided into three groups. The first group was given Intermittent fasting, the second was given Low-energy balanced diet, the third group underwent routine care for self-weight management. Relevant information such as body morphology ,glycolipid metabolism and tumor outcomes of the subjects were collected. By evaluating the tumor outcome and changes in glycolipid metabolism indicators, to confirm the effectiveness and safety of diet interventions for overweight and obese patients with endometrial cancer and treatd with fertility preservation.
Eligibility Criteria
Inclusion Criteria: * age ≥18 years old * diagnosed as endometrial cancer or atypical hyperplasia * fertility-preserving therapy * BMI≥25 kg/m2 * informed consent. Exclusion Criteria: * those with communication barriers * pregnant women * medical and surgical serious complications: urinary calculi, history of renal failure or severe renal insufficiency, familial dyslipidemia, severe liver disease, chronic metabolic acidosis, history of pancreatitis, severe diabetes mellitus, active gallbladder disease, fat dyspepsia, severe cardiovascular and cerebrovascular diseases.
Contact & Investigator
Li Xiaodan, Master
STUDY CHAIR
Peking University People's Hospital
Frequently Asked Questions
Who can join the NCT07318727 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 40 Years, studying Endometrium Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07318727 currently recruiting?
Yes, NCT07318727 is actively recruiting participants. Contact the research team at lxd_2000_510@163.com for enrollment information.
Where is the NCT07318727 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT07318727 clinical trial?
NCT07318727 is sponsored by Peking University People's Hospital. The principal investigator is Li Xiaodan, Master at Peking University People's Hospital. The trial plans to enroll 81 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.